Researchers at Xi'an Jiaotong-Liverpool University developed a new method that enables the efficient production of cysteine-rich peptides and microproteins in their naturally folded 3D structure. The approach uses organic solvents to mimic nature's oxidative folding process, resulting in speeds of over 100,000 times faster than aqueous...
A study published in Genome Medicine uses digital twins to computationally treat thousands of medications in individual patients with autoimmune diseases, finding promising results in mice and human tissue samples. The technology has the potential to revolutionize precision medicine by providing tailored medication for each patient.
Research reveals that FoxO6 upregulates ApoC3, leading to increased lipid accumulation and liver damage in aged rats on a high-fat diet. The study suggests that targeting this pathway may offer therapeutic strategies against hepatic steatosis.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
A new multitasking substance has been identified to prevent and treat both flu and COVID-19 infections concurrently. The long-acting recombinant cytokine protein rhIL-7-hyFc demonstrated therapeutic and preventive effects against various respiratory diseases, including COVID-19, influenza virus, and respiratory syncytial virus.
Researchers have identified a potential therapeutic target for Borjeson-Forssman-Lehman Syndrome, a neurodevelopmental disorder characterized by seizures and intellectual disability. The study found that PHF6 gene mutations impair Ephrin receptor regulation, leading to neural stem cell misregulation.
Researchers have identified a subset of T-cells that acts like stem cells and continuously generates effector T-cells that attack transplanted organs. Targeting the transcription factor IRF4 may lead to innovative therapies for patients with chronic infections, cancers, autoimmune diseases and transplanted organs.
A new study from the University of Colorado Anschutz Medical Campus suggests that managing circadian rhythms through intense light and chronologically timed therapy can help prevent or treat various circulatory system conditions, including heart disease. The research found that intense light stabilizes the PER2 gene and increases level...
Resmetirom, a new medication, has been approved to treat metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage of MASLD characterized by liver inflammation and scarring. The drug was shown to improve fibrosis and reduce disease progression in patients with MASLD.
A scoping review of literature found associations between cannabis use and non-cancerous urogenital illnesses like acute kidney injury and urinary retention. However, the data also suggest a therapeutic role of cannabis in certain urological conditions.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
A new study suggests that mushroom extract containing psilocybin demonstrates superior efficacy in stimulating neuroplasticity and promoting new connections between nerve cells. The research found that the extract had a more potent and prolonged impact on synaptic plasticity compared to chemically synthesized psilocybin.
Scientists from the University of Cologne developed threofuranosyl nucleic acid (TNA) with a new base pair, offering improved stability and function compared to natural DNA and RNA. This breakthrough could enable targeted drug delivery, diagnostics, and recognition of viral proteins or biomarkers.
Research reveals oestrogen's protective role in preventing fatty liver disease by targeting the TEAD1 protein. The discovery could lead to a new treatment for fatty liver and liver cancer, as well as earlier detection methods.
Researchers at the University of Cincinnati Cancer Center have identified a new protein called p47 that helps prevent breast cancer metastasis. The study found that lower p47 expression was correlated with higher breast cancer metastasis, and that increasing p47 function could potentially lead to new therapies.
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
Researchers have made a breakthrough in developing genetic treatments for hereditary conditions like cystic fibrosis and inherited vision loss. They created a new type of lipid nanoparticle, called Thio-lipids, that can deliver therapeutic payloads to the lungs and retina.
UCSF scientists discover delivering therapeutic molecules to amniotic fluid can effectively treat Angelman syndrome and other neurological conditions. The treatment uses antisense oligonucleotides, which can alter gene expression, and has shown improved motor function and learning outcomes in mice.
Researchers analyzed access to new treatments for early-stage lung cancer in Europe, highlighting existing disparities in healthcare systems and reimbursement structures. The study calls for a collective European approach to reduce inequalities in access to care.
Researchers discovered a potential treatment for Alzheimer's disease also prevents Type 2 diabetes by blocking the formation of toxic IAPP clusters. A synthetic peptide was shown to bind and neutralize these clusters, keeping beta cells alive.
Researchers found that rapamycin extends lifespan by regulating the activity of protein S6K, which influences the endolysosomal system. This leads to improved immune function and clearance of bacterial infections at old age.
The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.
A new study found that high-dose inhaled nitric oxide improves oxygenation and reduces mortality risk among critically ill Black patients with COVID-19. The treatment was more effective for Black patients, who have a suppressed nitric oxide system at baseline.
Scientists have developed a new way to alter the DNA of bacterial cells using high-frequency radio waves, outperforming traditional industry techniques. The process shows high efficiency and gentleness, with 91% of E. coli cells taking on the DNA after just three minutes.
After 7 to 12 years of follow-up, bariatric surgery outperformed medical/lifestyle intervention in achieving superior glycemic control with reduced medication use and higher rates of diabetes remission. Individuals who underwent bariatric surgery had better long-term management of their type 2 diabetes.
Researchers decode underlying mechanisms of DCM, hippocampal neurotoxicity, and dysbiosis mediated AD progression using mass spectrometry imaging. The studies found metabolic changes in DCM rat hearts and regulation of CYPs in the hippocampus, providing new perspectives on treatment strategies.
The Almodóvar lab is studying the link between HIV and pulmonary hypertension, a condition that increases pressure in lung arteries. By examining the interactions between different cell types and using a humanized mouse model, researchers hope to propose novel therapies to prevent lung diseases in people with HIV.
A novel chemotherapy approach uses patient's own cells as Trojan horses to deliver targeted cancer-killing drugs to lung cancer cells. The method has shown promise in reducing tumor size and improving treatment efficacy with minimal collateral damage to healthy tissues.
A UCF-developed technology uses a plasmonic platform to detect the chirality of molecules with high precision, enabling more accurate drug development and therapies. The platform improves upon current methods with sensitivity nearly 13 orders of magnitude greater.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
Scientists create 'μkiss' technique for precise delivery of materials to individual cells, offering new possibilities in single-cell science and next-generation therapeutic applications. The method provides full control over location, time, and scale of material application, enabling detailed studies of cellular processes.
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures. This discovery could be useful in treatment to reverse Alzheimer’s Disease impact by degrading amyloid plaques.
Scientists at CeMM Research Center have discovered a new method to mark proteins for destruction, potentially treating diseases like cancer. The technique uses 'intramolecular bivalent glues' to alter the protein's surface, triggering targeted protein degradation via ubiquitin ligases.
Researchers at Texas A&M University have developed a coating that bolsters the safety of fresh produce and provides enhanced protection against bacteria and fungi. The coating combines wax with nano-encapsulated cinnamon-bark essential oil in protein carriers to enhance antibacterial properties.
A new study published in LANCET eClinicalMedicine found that regular exercise can help individuals maintain weight loss after completing medical weight loss treatment. The study showed that exercising just two hours a week can lead to better quality of life, improved mental health, and reduced fatigue.
A new study suggests that individuals with low income are frequently misdiagnosed and lack access to effective treatment for eating disorders. Researchers offer guidelines for therapists to make accommodations for these patients, including providing government or local food resources and engaging with local food banks.
Researchers at Tohoku University have developed a novel monoclonal antibody targeting HER2-positive breast cancer cells, providing a new tool for treating this aggressive subtype. The antibody disrupts cell growth and proliferation while minimizing harm to surrounding healthy tissue.
Researchers developed protein-like polymers to disrupt the Keap1/Nrf2 protein-protein interaction, preventing cellular damage and oxidative stress. This approach holds promise for treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
In a phase 2 clinical trial, zilebesiran significantly reduced 24-hour mean ambulatory systolic blood pressure in adults with mild to moderate hypertension. The treatment was administered subcutaneously at varying doses and intervals, demonstrating its potential as an RNA interference therapeutic for managing hypertension.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Scientists at the University of California, Riverside, have identified 898 RNA-dependent proteins in the deadliest human malaria parasite, Plasmodium falciparum. These findings could lead to novel therapeutic targets against malaria and highlight the importance of RNAs in biological pathways in the parasite.
A retrospective study found that PRRT was effective in controlling hypoglycemia in 81% of patients with malignant insulinomas, enabling 58% to reduce medication use. The treatment resulted in improved symptom control and reduced potential drug side effects for over 80% of patients.
Researchers discovered that aggregates prevent silencing of stress response in brain cells, leading to cell death. A new treatment involves administering a drug to turn off the stress response and keeping SIFI turned on to clean up protein aggregates.
A new tumor spatial mapping tool will help clinicians assess the aggressiveness of cancer and personalize treatment. The tool maps the functional state of oncoproteins onto tumour images, allowing for more accurate diagnosis and informed treatment decisions.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
A randomized clinical trial of 1,015 participants found that apixaban did not significantly reduce recurrent stroke risk compared to aspirin in patients with cryptogenic stroke and atrial cardiopathy. The study suggests that alternative treatments may be more effective for preventing stroke recurrence in these patients.
Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.
Researchers discovered a new role for Mfsd7c in exporting excessive choline from the brain. The study suggests that targeting this protein could lead to therapeutic interventions for Alzheimer's disease and other neurological disorders.
A phase II clinical trial found Muse cell-based product CL2020 to be highly tolerated and improved ALS symptoms, but may not halt disease progression. The treatment's efficacy depends on combining it with other drugs for future treatments.
In a new study, researchers have identified a specific epigenetic pathway involved in the development of therapy resistance in melanoma. The study found that targeting this pathway with a small molecule inhibitor called corin can successfully resensitize therapy-resistant cancers to targeted therapies.
Researchers identified a next-generation BTK degrader that can destroy cellular targets and shrink tumors in drug-resistant CLL patients. The compound, NX-2127, showed promising results in laboratory studies and a phase 1 clinical trial.
A new study found that combining brain stimulation with intense physical rehabilitation helped stroke survivors recover movement in their arms and hands and maintain these improvements for one year. The pairing of rehabilitation therapy with vagus nerve stimulation likely helps the brain strengthen new neural pathways.
Researchers grew lab-tumours from patient tissue to accurately predict drug effectiveness, showing high accuracy in identifying effective treatments and rejecting ineffective ones. The study paves the way for revolutionising personalised medicine and clinician-patient care through improved treatment selection.
Researchers found that SGLT2 inhibitors reduced kidney stone rates by 30% compared to GLP1 agonists and 25% compared to DPP4 inhibitors. The study included data from 716,406 adults with type 2 diabetes who took these medications.
Researchers identified senescence-related tumor microenvironment genes associated with poor prognosis, genetic alterations, and reduced responsiveness to immunotherapy in HNSC. The study highlights the importance of precision medicine approaches for personalized treatment.
A Rutgers University study found that long-acting antipsychotic injections reduced 30-day rehospitalization rates for patients with schizophrenia or schizoaffective disorder by 75% compared to oral medication. This shift can have significant financial and medical benefits for both patients and hospitals.
A new tool, developed with a machine learning-based approach, can predict diuretic response in patients with ADHF. The BAN-ADHF score may lead to personalized strategies for effectively managing congestion in hospitalized patients.